EurekaMag.com logo
+ Site Statistics
References:
53,214,146
Abstracts:
29,074,682
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on Google+Follow on Google+
Follow on LinkedInFollow on LinkedIn

+ Translate

Electrophysiologic and biochemical studies on the putative calcium channel blocker mdl 12330a in an endocrine cell


Journal of Pharmacology & Experimental Therapeutics 243(1): 402-407
Electrophysiologic and biochemical studies on the putative calcium channel blocker mdl 12330a in an endocrine cell
MDL 12,330A is a molecule structurally unrelated to other organic Ca++ channel ligands that may alter Ca++ channel function. Using whole cell patch clamp, [3H]PN200-110 binding and 45Ca++ uptake studies, we examined the effects of this compound on voltage-dependent Ca++ channels in rat anterior pituitary cells. At a concentration of 10-5Ca++ uptake studies, we examined the effects of this compound on voltage-dependent Ca++ channels in rat anterior pituitary cells. At a concentration of 10-5 M, MDL 12,330A showed little effect on outward K+ current, Na+ current or low-threshold Ca++ current in this cell line. At 10-6 M, MDL12, 330A reversibly inhibited slow Ca++ current in a voltage-dependent manner. 45Ca++ uptake was also blocked by this compound at 10-6 M, whereas [3H]PN200-110 binding was stimulant concentrations of 10-7 to 10-6 M. The results are consistent with an interaction of MDL 12,330A with slow Ca++ channels at a site allosterically linked to the 1,4-dihydropyridine binding site.

(PDF 0-2 workdays service: $29.90)

Accession: 005349241



Related references

Electrophysiologic and biochemical studies on the putative Ca++ channel blocker MDL 12,330A in an endocrine cell. Journal of Pharmacology and Experimental Therapeutics 243(1): 402-407, 1987

Electrophysiological and biochemical studies on the putative calcium channel antagonist mdl 12330a. Federation Proceedings 46(3): 394, 1987

Hemodynamic and electrophysiologic effects of amlodipine, a new calcium channel blocker. American Journal of Cardiology 64(17): 71i-77i, 1989

Hemodynamic and electrophysiologic effects of amlodipine a new long acting calcium channel blocker. European Heart Journal 10(ABSTR SUPPL): 37, 1989

Bepridil electrophysiologic and arrhythmogenic profile of a new calcium channel blocker used in the treatment of hypertension. Hypertension (Dallas) 13(5): 536, 1989

The combination of OLmesartan and a CAlcium channel blocker (azelnidipine) or candesartan and a calcium channel blocker (amlodipine) in type 2 diabetic hypertensive patients: the OLCA study. Diabetes & Vascular Disease Research 9(4): 280-286, 2013

Combined effect of angiotensin II receptor blocker and either a calcium channel blocker or diuretic on day-by-day variability of home blood pressure: the Japan Combined Treatment With Olmesartan and a Calcium-Channel Blocker Versus Olmesartan and Diuretics Randomized Efficacy Study. Hypertension 59(6): 1132-1138, 2012

Interaction of kb 944 and mdl 12330a with the calcium entry blocker receptor complex in cardiac sarcolemmal membrane vesicles. Federation Proceedings 46(6): 1984, 1987

Effects of the putative P-type calcium channel blocker, R,R-(-)-daurisoline on neurotransmitter release. Naunyn-Schmiedeberg's Archives of Pharmacology 352(6): 670-678, 1995

Initial angiotensin-converting enzyme inhibitor/calcium channel blocker combination therapy achieves superior blood pressure control compared with calcium channel blocker monotherapy in patients with stage 2 hypertension. American Journal of Hypertension 17(6): 495-501, 2004